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Io the Editor: Large interindividual variability in the response to
spirin and clopidogrel (oral antiplatelet agents [OAA]) is known to
xist, and previous studies showed that poor response to OAA is
ssociated with higher risk of ischemic complications after percuta-
eous coronary intervention (PCI) (1–3).Whether poor responders to
AA display similar inadequate platelet inhibition (PI) also after
lycoprotein (GP) IIb/IIIa inhibitor administration remains
ndefined.
This is a pre-specified mechanistic substudy of the 3T/2R (Tai-
oring Treatment with Tirofiban in patients showing Resistance to
spirin and/or Resistance to clopidogrel) trial (4). Accordingly, inclu-
ion and exclusion criteria, study design, screening procedure, defini-
ions, primary end point, and sample size have been previously
eported (4,5). Briefly, we evaluated tirofiban responsiveness in a
andom selection of full versus poor responders to OAA (31 vs. 31
atients) and clopidogrel responsiveness in full versus poor responders
o aspirin (15 vs. 15 patients). In all patients, before clopidogrel intake,
lood was sampled to evaluate baseline platelet reactivity (PR) with
ight transmission aggregometry (20 M of adenosine diphosphate).
o assess clopidogrel and tirofiban responsiveness (using VerifyNow
2Y12 and IIb/IIIa assays [Accumetrics Inc., San Diego, California],
espectively [4,5]), blood samples were collected 1, 2, 6, 18, and 24 h after
he start of the therapy. Continuous data are shown as mean  SD.
omparisons between 2 ormore groupswere performed by Student t test
nd analysis of variance. Probability was significant at a level of p 0.05.
nalysis was performed using STATISTICA version 8 (Statsoft Inc,
ulsa, Oklahoma).
Patient populations were well matched for age, cardiovascular risk
actors, clinical presentation, and vessel disease. Baseline PR was signifi-
antly higher in poor responders to OAA (58 8 P2Y12 reactivity units
PRU] vs. 48  12 PRU, p  0.01), as assessed by light transmission
ggregometry. This finding was also confirmed by analyzing only poor
esponders to aspirin or those to clopidogrel.One hour (T1) after tirofiban
nfusion, no differences were noted in PI between full versus poor
esponders to OAA (Fig. 1A). Twenty-nine (93%) full responders to
AA and 28 (90%) poor responders to OAA showed full response to
irofiban (PI90%) at T1 (p 0.9). Moreover, PI by tirofiban did not
iffer at any time point (Fig. 1B). Two hours after a 600-mg loading dose
f clopidogrel, aspirin poor responder patients showed a very low PI (20
23% vs. 56 23%, p 0.01) with higher residual on-treatment PR
200 62 PRU vs. 115 64 PRU, p 0.01), as compared with aspirin
ull responder patients (Figs. 1C and 1D). According to the used
efinition, 14 (93%) aspirin poor responders were also clopidogrel poor
esponders, as compared with 3 (20%) aspirin full responders (p 0.03).
t 1-month follow-up, no major ischemic and bleeding complications
ccurred. EThis study shows that poor responders to aspirin and/or clopi-
ogrel have levels of PI by tirofiban, which are comparable to those
chieved in full aspirin and clopidogrel responders. Tirofiban re-
ponse, evaluated both as a continuous variable and as full response,
id not differ between poor versus full responders to aspirin/
lopidogrel at any time point. Our study carries important clinical
mplications because previous reports consistently showed that pa-
ients undergoing PCI with high on-treatment (aspirin and/or clopi-
ogrel) PR are at heightened risk of peri-procedural myocardial
nfarction (MI) (1,2). We provide, for the first time, the mechanistic
vidence supporting the use of a GP IIb/IIIa inhibitor to overcome,
uring PCI, high on-treatment PR and to reduce the rate of
eri-procedural MI in this subset of patients (5). Although not
ntirely conclusive, peri-procedural MI has been consistently associ-
ted with worse clinical outcome. This notion is of paramount
mportance in stable and low-risk patients (as those recruited in the
T/2R study [5]) in whom coronary revascularization does not
ignificantly decrease mortality or overall MI rate (6).
Poor response to aspirin and to clopidogrel have been shown to be
requently associated (2). In our study, aspirin poor responders showed a
ower PI by clopidogrel and were more frequently clopidogrel poor
esponders. Interestingly, responsiveness to clopidogrel also increases
hroughout time in poor responder patients. Nevertheless, response to
lopidogrel still remained suboptimal compared with that of full
esponders. Thus, a strategy of GP IIb/IIIa inhibitor administration
emains attractive to reduce the peri-procedural ischemic burden of
igh on-treatment PR, especially in clinical settings where delaying
he procedure to allow more complete PI is not acceptable (3).
Our study was designed as a proof of concept mechanistic inves-
igation; its sample size is relatively small and therefore does not allow
or definitive conclusions. Moreover, we enrolled highly selected
atients who were at low risk. Thus, our findings cannot be automat-
cally extrapolated to higher-risk patients.
We concluded that poor responders to aspirin and/or clopidogrel
ndergoing PCI show a PI by tirofiban that is comparable to that
bserved in full responders, explaining the previously reported benefit
n reducing peri-procedural MI as compared with standard care (5).
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